Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Convalescent Plasma for Severely Ill COVID-19
NCT04388527Phase 1Completed
- Sponsor
- University of Pennsylvania
- Start
- Apr 2020
- Primary completion
- Jan 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of COVID-19 convalescent plasma in coronavirus disease 2019 (COVID-19), sponsored by University of Pennsylvania. Primary endpoints: Participants With Serious Adverse Events and Time to Clinical Improvement. Started Apr 2020; status: completed.
02
Drugs
COVID-19 convalescent plasma
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04388527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04388527.